vs
Side-by-side financial comparison of AtriCure, Inc. (ATRC) and Beta Bionics, Inc. (BBNX). Click either name above to swap in a different company.
AtriCure, Inc. is the larger business by last-quarter revenue ($140.5M vs $27.6M, roughly 5.1× Beta Bionics, Inc.). On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs 13.1%).
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
ATRC vs BBNX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $140.5M | $27.6M |
| Net Profit | — | $-21.9M |
| Gross Margin | 75.0% | 59.5% |
| Operating Margin | 1.8% | — |
| Net Margin | — | -79.3% |
| Revenue YoY | 13.1% | 56.6% |
| Net Profit YoY | — | 23.6% |
| EPS (diluted) | $0.04 | $-0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $27.6M | ||
| Q4 25 | $140.5M | $32.1M | ||
| Q3 25 | $134.3M | $27.3M | ||
| Q2 25 | $136.1M | $23.2M | ||
| Q1 25 | $123.6M | $17.6M | ||
| Q4 24 | $124.3M | — | ||
| Q3 24 | $115.9M | — | ||
| Q2 24 | $116.3M | — |
| Q1 26 | — | $-21.9M | ||
| Q4 25 | — | $-13.5M | ||
| Q3 25 | $-267.0K | $-14.2M | ||
| Q2 25 | $-6.2M | $-16.9M | ||
| Q1 25 | $-6.7M | $-28.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.9M | — | ||
| Q2 24 | $-8.0M | — |
| Q1 26 | — | 59.5% | ||
| Q4 25 | 75.0% | 59.0% | ||
| Q3 25 | 75.5% | 55.5% | ||
| Q2 25 | 74.5% | 53.8% | ||
| Q1 25 | 74.9% | 50.9% | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 74.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | -50.2% | ||
| Q3 25 | 0.2% | -62.5% | ||
| Q2 25 | -4.5% | -85.5% | ||
| Q1 25 | -4.8% | -105.7% | ||
| Q4 24 | -11.7% | — | ||
| Q3 24 | -6.4% | — | ||
| Q2 24 | -6.2% | — |
| Q1 26 | — | -79.3% | ||
| Q4 25 | — | -41.9% | ||
| Q3 25 | -0.2% | -52.1% | ||
| Q2 25 | -4.5% | -72.6% | ||
| Q1 25 | -5.5% | -162.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.8% | — | ||
| Q2 24 | -6.9% | — |
| Q1 26 | — | $-0.49 | ||
| Q4 25 | $0.04 | $-0.16 | ||
| Q3 25 | $-0.01 | $-0.33 | ||
| Q2 25 | $-0.13 | $-0.39 | ||
| Q1 25 | $-0.14 | $-0.93 | ||
| Q4 24 | $-0.33 | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.4M | $199.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $491.9M | $271.2M |
| Total Assets | $654.2M | $304.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $199.5M | ||
| Q4 25 | $167.4M | $219.1M | ||
| Q3 25 | $147.9M | $228.7M | ||
| Q2 25 | $117.8M | $249.7M | ||
| Q1 25 | $99.9M | $231.5M | ||
| Q4 24 | $122.7M | — | ||
| Q3 24 | $130.3M | — | ||
| Q2 24 | $114.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
| Q1 26 | — | $271.2M | ||
| Q4 25 | $491.9M | $287.6M | ||
| Q3 25 | $476.5M | $294.8M | ||
| Q2 25 | $464.5M | $301.6M | ||
| Q1 25 | $454.6M | $313.8M | ||
| Q4 24 | $461.0M | — | ||
| Q3 24 | $465.0M | — | ||
| Q2 24 | $462.1M | — |
| Q1 26 | — | $304.4M | ||
| Q4 25 | $654.2M | $328.7M | ||
| Q3 25 | $635.4M | $330.0M | ||
| Q2 25 | $608.8M | $330.0M | ||
| Q1 25 | $591.6M | $338.0M | ||
| Q4 24 | $609.3M | — | ||
| Q3 24 | $615.1M | — | ||
| Q2 24 | $597.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0M | — |
| Free Cash FlowOCF − Capex | $18.4M | — |
| FCF MarginFCF / Revenue | 13.1% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $48.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $-8.6M | ||
| Q3 25 | $26.7M | $-8.7M | ||
| Q2 25 | $21.6M | $-13.6M | ||
| Q1 25 | $-11.0M | $-20.0M | ||
| Q4 24 | $5.8M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $7.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $-10.5M | ||
| Q3 25 | $24.1M | $-10.0M | ||
| Q2 25 | $19.0M | $-15.4M | ||
| Q1 25 | $-13.2M | $-20.3M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $16.4M | — | ||
| Q2 24 | $5.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | -32.8% | ||
| Q3 25 | 18.0% | -36.7% | ||
| Q2 25 | 13.9% | -66.2% | ||
| Q1 25 | -10.7% | -115.1% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 4.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 5.9% | ||
| Q3 25 | 1.9% | 4.7% | ||
| Q2 25 | 2.0% | 7.7% | ||
| Q1 25 | 1.8% | 1.9% | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 2.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
BBNX
Segment breakdown not available.
